Track 1: Dementia

Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Other common symptoms include emotional problems, problems with language, and a decrease in motivation. A person's consciousness is usually not affected. A dementia results in a change from a person's usual mental functioning and a greater decline than one would expect due to aging. These diseases also have a significant effect on a person's caregivers

Track 2:  Alzheimers disease

Alzheimers disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia. The most common early symptom is difficulty in remembering recent events short-term memory loss. [As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioural issues. As a person's condition declines, they often withdraw from family and society.  Gradually, bodily functions are lost, ultimately leading to death.

Track 3: Vascular Dementia

Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. This death of brain cells can cause problems with memory, thinking or reasoning. Together these three elements are known as cognition. When these cognitive problems are bad enough to have a significant impact on daily life, this is known as vascular dementia.

Track 4: Frontotemporal dementia

Frontotemporal dementia is an uncommon type of dementia that mainly affects the front and sides of the brain (frontal and temporal lobes) and causes problems with behaviour and language. Dementia mostly affects people over 65, but front temporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, Frontotemporal dementia tends to develop slowly and get gradually worse over several years. Frontotemporal dementia is misdiagnosed as a psychiatric problem or as Alzheimer's disease.

Track 5: Neurodegenerative Diseases

Neurodegenerative diseases cause your brain and nerves to deteriorate over time. They can change your personality and cause confusion. They can also destroy your brain’s tissue and nerves. Some brain diseases, such as Alzheimer’s disease, may develop as you age. They can slowly impair your memory and thought processes. Other diseases, such as Tay-Sachs disease, are genetic and begin at an early age.

Track 6:  Brain diseases

The brain is body’s control center. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your five senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes those conditions that are caused by illness, genetics, or traumatic injury.

Track 7: Parkinson’s diseases

Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Track 8: Anxiety & Depression

Apathy, depression and anxiety are common conditions experienced by people with dementia. They are known as psychological conditions because they can affect a person’s emotional and mental health. Anxiety is more than just feeling stressed or worried. Anxious feelings are a normal reaction to a situation where a person feels under pressure and usually pass once the stressful situation has passed, or the ‘stressor’ is removed. Depression affects how a person feels about themselves. A person may lose interest in work, hobbies and doing things he or she normally enjoys. Some people may lack energy, have difficulty sleeping or sleep more than usual, while some people feel anxious or irritable and find it hard to concentrate.

Track 9: Animal Models in Dementia

Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development have been carried out. Animal models have contributed noticeably to these advances and are an indispensable part in the evaluation of therapeutics. This review is an exhaustive study of animal models of dementia and cognitive dysfunction. A thorough and critical evaluation of current rodent models of dementia and discussion about their role in drug discovery and development has been carried out.

Track 10: Amyloid protein in dementia

Amyloid Plaques One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid is a general term for protein fragments that the body produces normally. Beta amyloid is a protein fragment snipped from an amyloid precursor protein (APP)

Track 11: Diagnosis of dementia

Diagnosing dementia and determining what type it is can be challenging. A diagnosis of dementia requires that at least two core mental functions be impaired enough to interfere with daily living. They are memory, language skills, ability to focus and pay attention, ability to reason, solve problem and visual perception

 Track 12: Nursing care in Dementia

Nurses provide the specialist dementia support that families need. When things get challenging or difficult, our nurses work alongside people with dementia, and their families: giving them one-to-one support, expert guidance and practical solutions.

 Track 13: Dementia Management

There is no cure for dementia, so the chief goals of treatment are to:

a. Maintains quality of life

b. Enhances cognition, mood and behaviour

c. Fosters a safe environment

d. Promotes social engagement

Track 14: Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

Track 15: Recent Advancement in Treatments of Dementia

Epidemiological studies show that, worldwide, the number of people aged over 65 will increase substantially in the next decades and that a considerable proportion of this population will develop dementia. Ample evidence shows that ageing is associated with a high rate of painful conditions, irrespective of cognitive status. The number of patients with dementia who will experience painful conditions is therefore likely to increase.

Tack 16: Clinical Trials & Case Reports in Dementia

The goal of much of the research activity in dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently under diagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically the distinction is important, because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.

Theme: Exploring the Challenges and Excellence in Dementia Research

Dementia congress 2020 welcomes attendees, presenters, and exhibitors from all over the world to Singapore. We are delighted to invite you all to attend and register for the “14^th World Congress on Advances and Innovations in Dementia” which is going to be held during August 26-27, 2020 Singapore.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Dementia congress 2020, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Dementia congress 2020 organizing committee look forward to meeting you in Singapore.

For more details please visit - http://dementiacongress.neurologyconference.com

Why in Singapore?

One in 10 people aged 60 and above in Singapore have dementia, according to a new nationwide study. Findings on how common the illness is and its impact on caregivers emerged on Wednesday from the $4.4 million Well-being of the Singapore Elderly (WiSE) study, which interviewed almost 5,000 seniors and their family members. Its growing prevalence is a concern, according to Institute of Mental Health experts who collaborated with other international investigators for the three-year research. Most countries have a prevalence rate of 5 to 7 per cent, though researchers from IMH said countries that used the same diagnostic tool as the one in the WiSE study, such as urban China and India, registered an 8 per cent prevalence. A World Health Organisation survey on ageing carried out here 20 years ago found that only 3 per cent were diagnosed with dementia. Professor Chong Siow Ann, vice-chairman of the IMH's medical board (research), who led the WiSE study, said: "The concern is how we can use the study to assess if we have adequate resources to meet the challenges we have right now and those that are going to be emerging." IMH experts attribute the rise in prevalence rate to a rapidly ageing population and increasing prevalence of stroke, obesity, diabetes and hypertension that are risk factors for dementia. Patients with dementia, a progressive brain disorder, may suffer from memory loss and have difficulty expressing themselves. In 2012, about 28,000 people in Singapore aged 60 and older had dementia. The number is expected to soar to 80,000 by 2030. The study also found that age, stroke as well as education and employment were associated factors. Caregivers of those with dementia also report significantly higher levels of distress and psychological problems compared to other caregivers.

According to the latest Well-being of the Singapore Elderly (WiSE) study conducted by the Institute of Mental Health (IMH), one in 10 people aged 60 and above in Singapore has dementia. The results of this study, funded by the Ministry of Health and the Singapore Millennium Foundation, which involved about 5,000 elderly and their caregivers over a period of three years, are cause for concern. In 2012, a total of 28,000 Singaporeans above the age of 60 had dementia. This number is expected to rise to 80,000 by 2030, as Singapore’s population continues to age.

Importance and Scope:

The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.

Someone in the world develops dementia every 3 seconds. There were an estimated 46.8 million people worldwide living with dementia in 2015 and this number is believed to be close to 50 million people in 2017. This number will almost double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Much of the increase will be in developing countries. Already 58% of people with dementia live in low and middle income countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours.

Major Neuroscience Societies and Associations in Singapore:

Major Dementia and alzheimers Societies and Associations around Globe:

Top Neuroscience Universities in Singapore:

Top Neuroscience Universities in Globe:

Hospital Associated with Dementia :

Companies Associated with Dementia in Singapore

Top Dementia Companies:

Glance at market of dementia:-

The total estimated worldwide cost of dementia is US$818 billion in 2015, which represents 1.09% of global GDP. By 2018, the global cost of dementia will rise above a US$ trillion.

This figure includes costs attributed to informal care (unpaid care provided by family and others), direct costs of social care (provided by community care professionals, and in residential home settings) and the direct costs of medical care (the costs of treating dementia and other conditions in primary and secondary care).

Direct medical care costs account for roughly 20% of global dementia costs, while direct social sector costs and informal care costs each account for roughly 40%. The relative contribution of informal care is greatest in the African regions and lowest in North America, Western Europe and some South American regions, while the reverse is true for social sector costs.

This means that if global dementia care were a country, it would be the 18th largest economy in the world. The annual costs exceed the market values of companies such as Apple (US $742 billion) and Google (US $368 billion). More information is available in our World Alzheimer Report 2015.

Some products manufactured by the industry related Neuroscience Research:-

•  NeuroScience ImmuWell.
• NeuroScience AdreCor.
• NeuroScience Calm CP.
• Kavinace .
• Purified anti-β-Dystroglycan Antibody.
• Alexa Fluor® 594 anti-Neurofilament H (NF-H), Phosphorylated Antibody.
• Mouse & Rat  Spinal Cord Matrices.
• Surgical & Dissection Tools. 

Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease

Ebixa®

Aricept™

References:

http://www.alzheimers.org.uk/dementiauk

https://en.wikipedia.org/wiki/Alzheimer's_Research_UK

http://www.alzheimersresearchuk.org/

http://www.alz.org/uk/dementia-alzheimers-uk.asp

http://www.alzheimersresearchuk.org/about-dementia/facts-stats/

http://www.alz.org/research/funding/alzheimers_our_commitment.asp

https://www.ucl.ac.uk/dementia

http://www.city.ac.uk/courses/cpd/evidence-based-dementia-care

http://www.kcl.ac.uk/ioppn/depts/oldage/research/bdr.aspx